CABOMETYX® is indicated for the treatment of advanced renal cell carcinoma (RCC):1
– in treatment-naïve adults with intermediate or poor risk
– in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy

1. CABOMETYX® SmPC